EUCTR2007-001645-17-GB进行中(未招募)不适用
Prevention of Established Pulmonary Hypertension in High Risk patients with Fibrotic Lung Disease – a double-blinded, randomised, placebo controlled trial with endothelin-1 receptor antagonist therapy - Prevention of Pulmonary Hypertension in Interstitial Lung Disease
Royal Brompton and Harefield NHS Trust0 个研究点开始时间: 2007年10月10日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中(未招募)
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Patients >=18yrs, <80yrs
- •2. Patients with Idiopathic Pulmonary Fibrosis or fibrotic Non-Specific Pneumonitis according to ATS/ERS criteria.
- •3. Patients with mild pulmonary hypertension or at risk of developing pulmonary hypertension (Pre-PH), as defined by:
- •o Mild-PH: RHC: mean PAH 25-35mmHg, PCWP<15mmHg, and 6-minute walk test oxygen desaturation <89%
- •o Pre-PH: RHC: mean PAP <25mmHg, PCWP<15mmHg, 6-minute walk test oxygen desaturation <89%
- •4. Patients providing written informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Patients <18, >80yrs.
- •2. Patients with unstable disease, or an acute exacerbation of their underlying fibrotic lung disease.
- •3. Patients with significant other organ co-morbidity including hepatic or renal impairment.
- •4. Patients with systolic BP < 85mmHg
- •5. Patients with other conditions that may affect the ability to perform a 6-minute walk test.
- •6. Patients unable to provide informed consent and comply with the patient protocol.
- •7. Patients receiving excluded medications (including: epoprostenol, or prostacyclin analogues, phosphodiesterase inhibitors, other endothelin receptor antagonists, drugs with potential interaction with bosentan such as glibenclamide, fluconazole, cyclosporin A, or tacrolimus, and other invesgational agents).
- •8. Patients with planned surgical intervention during the study period.
- •9. Pregnant patients
- •10. Patients with resting oxygen saturation <90%
- •11. Patients with clinically overt ischaemic heart disease
- •12. Patients with predominant emphysema on CT scan (in excess of interstitial changes)
研究者
相似试验
进行中(未招募)
1 期
Racecadotril used in combination with sildenafil to reduce blood pressure in the lungs.Pulmonary hypertensionMedDRA version: 14.1 Level: PT Classification code 10037400 Term: Pulmonary hypertension System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2012-003921-13-GBniversity College London21
进行中(未招募)
不适用
Behandling av förhöjt pulmonellt arteriellt tryck med inhalerad iloprost - IloprostEUCTR2004-001551-11-SEund University Hospital40
尚未招募
不适用
ong term blockage of pulmonary arteries and factors affecting its management.CTRI/2020/03/023978Dr Kuntal Surana
已完成
不适用
Pulmonary artERial hypertenSion: bonE morPHOgeNEtic protein signaling out of control (PERSEPHONE)1004697310037454Pulmonary arterial hypertensionNL-OMON55717VU medisch centrum100
已完成
不适用
Non-invasive Estimation of Pulmonary Artery Pressure in Healthy Subjects by Electrical Impedance TomographyPulmonary Artery PressureNCT02969486Insel Gruppe AG, University Hospital Bern30
